Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis

Mar, Javier; Mar-Barrutia, Lorea; Gimeno‐Ballester, Vicente; Miguel, Ramón San

doi:10.1016/j.medcle.2015.09.005

Cited by 1 publication

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Vallejo-Torres et al have updated this figure by taking into account the health expenditure of the different Spanish regions, and they estimated it between 22,000 and 25,000 euros / QALY (10). Our work showed an ICER much more favorable than in previous analyses estimated from the results of clinical trials (2,11,12,18), which is explained by the reduction in the cost of DAAs and the use of the absence of active treatment as reference. Both the analysis of the whole sample and that of patients with fibrosis stages 0 to 3 showed a result below the threshold.…”

Section: Discussioncontrasting

confidence: 47%

“…The CES based on clinical trials showed that the new DAAs were, in general, efficient from the perspective of the Spanish health system (2,(10)(11)(12). However, important differences may appear between the real-world practice and clinical trials regarding parameters of efficacy, safety, consumption of healthcare resources, or cost of medicines.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals

Mar¹,

Ibarrondo²,

Martínez-Baz³

et al. 2018

Rev Esp Enferm Dig

Self Cite

View full text Add to dashboard Cite

The high initial cost of antivirals against hepatitis C prompted development of the "Strategic Plan for Tackling Chronic Hepatitis C in the Spanish National Health System". The objective of this study was the economic evaluation of the first two years of its application in Navarre, Spain. The change in the natural history of hepatitis C produced by the sustained virological response (SVR) was compared to an alternative without treatment and modeled with patient-level data. By means of a discrete events simulation model, the cost-effectiveness and the budget impact analysis of the treatment program were measured from the perspective of the Navarre Health Service. Of 656 patients treated, 98% had SVR. The average cost of the treatments was 18,743 euros per patient. The incremental cost-effectiveness ratio (ICER) with discount was 5,346 euros per quality-adjusted life years, which became more efficient as the stage of fibrosis increased until it reached levels of dominance in stage 4 fibrosis. The associated costs for chronic liver disease decreased as the benefit of the treatment was expressed. The implementation of the Strategic Plan is cost-effective, with an ICER well below the threshold, since the cost of treatment is largely compensated by savings in long-term health expenditure. The budgetary impact foresees a net saving from the third year on. The two key parameters were the decrease in the price of the treatment and the SVR in nearly 100% of the patients.

show abstract

Section: Discussioncontrasting

confidence: 47%